13-Dec-2024
No headlines found.
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
Globe Newswire (Tue, 10-Dec 8:30 AM ET)
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
Globe Newswire (Mon, 4-Nov 8:30 AM ET)
Globe Newswire (Thu, 31-Oct 8:00 AM ET)
IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
Globe Newswire (Thu, 24-Oct 4:05 PM ET)
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Globe Newswire (Thu, 3-Oct 4:05 PM ET)
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Iradimed trades on the NASDAQ stock market under the symbol IRMD.
As of December 13, 2024, IRMD stock price declined to $52.63 with 71,161 million shares trading.
IRMD has a beta of 1.30, meaning it tends to be more sensitive to market movements. IRMD has a correlation of 0.27 to the broad based SPY ETF.
IRMD has a market cap of $666.44 million. This is considered a Small Cap stock.
Last quarter Iradimed reported $18 million in Revenue and $.43 earnings per share. This beat revenue expectation by $226,000 and exceeded earnings estimates by $.05.
In the last 3 years, IRMD traded as high as $57.95 and as low as $26.00.
The top ETF exchange traded funds that IRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
IRMD has underperformed the market in the last year with a price return of +22.8% while the SPY ETF gained +29.9%. However, in the short term, IRMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +8.9% vs +7.8% return in SPY. But in the last 2 weeks, IRMD shares have been beat by the market, returning -2.4% compared to an SPY return of +0.3%.
IRMD support price is $53.07 and resistance is $55.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRMD shares will trade within this expected range on the day.